Athersys, Inc. (ATHXQ)

Oncternal Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	0.08	5.33	5.51	1.44	5.63	24.29
Revenue Growth (YoY)	-98.67%	-3.43%	282.92%	-74.44%	-76.81%	555.10%
Cost of Revenue	18.78	56.29	71.08	62.99	39.05	38.66
Gross Profit	-18.7	-50.97	-65.57	-61.55	-33.41	-14.37
Selling, General & Admin	9.52	14.58	20.07	15.89	11.38	10.44
Operating Expenses	10.03	16	21.49	16.78	12.08	11.3
Operating Income	-28.73	-66.97	-87.06	-78.33	-45.49	-25.66
Other Non Operating Income (Expenses)	0.14	4.48	0.1	-0.43	0.91	0.76
EBT Excluding Unusual Items	-29.94	-62.49	-86.96	-78.77	-44.58	-24.9
Merger & Restructuring Charges	-2.83	-2.8	-	-	-	-
Asset Writedown	-10.21	-7.24	-	-	-	-
Pretax Income	-37.51	-72.53	-86.96	-78.77	-44.58	-24.28
Net Income	-37.51	-72.53	-86.96	-78.77	-44.58	-24.28
Net Income to Common	-37.51	-72.53	-86.96	-78.77	-44.58	-24.28
Shares Outstanding (Basic)	20	12	9	7	6	5
Shares Outstanding (Diluted)	20	12	9	7	6	5
Shares Change (YoY)	91.05%	33.15%	19.63%	23.59%	11.02%	21.94%
EPS (Basic)	-1.89	-6.07	-9.69	-10.50	-7.35	-4.44
EPS (Diluted)	-1.89	-6.07	-9.69	-10.50	-7.35	-4.44
Free Cash Flow	-24.71	-59.35	-77.55	-62.97	-35.91	-14.88
Free Cash Flow Per Share	-1.25	-4.97	-8.64	-8.40	-5.92	-2.72
Gross Margin	-	-	-	-	-	-59.14%
Operating Margin	-35908.75%	-1257.63%	-1578.85%	-5439.72%	-807.53%	-105.64%
Profit Margin	-46883.75%	-1362.14%	-1576.99%	-5469.79%	-791.44%	-99.97%
Free Cash Flow Margin	-30888.75%	-1114.50%	-1406.33%	-4373.06%	-637.41%	-61.27%
EBITDA	-28.22	-65.55	-85.63	-77.44	-44.79	-24.81
EBITDA Margin	-	-	-	-	-	-102.12%
D&A For EBITDA	0.51	1.42	1.43	0.89	0.7	0.86
EBIT	-28.73	-66.97	-87.06	-78.33	-45.49	-25.66
EBIT Margin	-	-	-	-	-	-105.64%
Revenue as Reported	0.08	5.33	5.51	1.44	5.63	24.29

Updated Nov 16, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.